Efficacy and safety of PANCREAZE® for treatment of exocrine pancreatic insufficiency due to cystic fibrosis Bruce C. Trapnell, Steven D. Strausbaugh,

Slides:

Advertisements

Similar presentations

Long-term non-invasive ventilation in cystic fibrosis — Experience over two decades William G. Flight, Jonathan Shaw, Susan Johnson, A. Kevin Webb, Andrew.

Advertisements

Use of the insulin pump in treat cystic fibrosis related diabetes Dana S. Hardin, Julie Rice, Mark Rice, Randall Rosenblatt Journal of Cystic Fibrosis.

Comparing age of cystic fibrosis diagnosis and treatment initiation after newborn screening with two common strategies Don B. Sanders, Huichuan J. Lai,

Safety and efficacy of Creon® Micro in children with exocrine pancreatic insufficiency due to cystic fibrosis Nataliya Y. Kashirskaya, Nikolay I. Kapranov,

Efficacy and safety of Creon�� 24,000 in subjects with exocrine pancreatic insufficiency due to cystic fibrosis Bruce C. Trapnell, Karen Maguiness, Gavin.

Ian D. Molyneux, Tanya Moon, A. Kevin Webb, Alyn H. Morice

Treatment compliance in children and adults with Cystic Fibrosis

Megan W. France, Mary E. Dodd, John R. Govan, Catherine J. Doherty, A

The immediate effect of musculoskeletal physiotherapy techniques and massage on pain and ease of breathing in adults with cystic fibrosis Annemarie Lee,

Pancreatic enzyme replacement therapy for young cystic fibrosis patients Anne Munck, Jean-Francois Duhamel, Thierry Lamireau, Bernard Le Luyer, Claire.

Cystic fibrosis research in allied health and nursing professions

Avani C. Modi, Crystal S. Lim, Nami Yu, David Geller, Mary H

Scott D. Sagel, Marci K. Sontag, Meg M

A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children.

Megan R. Nelson, Craig R. Adamski, Audrey Tluczek

Urinary incontinence in 9��16��year olds with cystic fibrosis compared to other respiratory conditions and a normal group W.J. Browne, C.J. Wood, M.

Measures of body habitus are associated with lung function in adults with cystic fibrosis: A population-based study Doug L. Forrester, Alan J. Knox,

Microbiological yield from induced sputum compared to oropharyngeal swab in young children with cystic fibrosis Marco Zampoli, Komala Pillay, Henri Carrara,

Comparison of two pancreatic enzyme products for exocrine insufficiency in patients with cystic fibrosis C.J. Taylor, R. Thieroff-Ekerdt, S. Shiff, L.

Cirrhosis and other liver disease in cystic fibrosis

Safety and efficacy of prolonged levofloxacin inhalation solution (APT-1026) treatment for cystic fibrosis and chronic Pseudomonas aeruginosa airway infection

The ease of breathing test tracks clinical changes in cystic fibrosis

Rate of improvement of CF life expectancy exceeds that of general population— Observational death registration study Matthew N. Hurley, Tricia M. McKeever,

Controlled clinical trials in cystic fibrosis — are we doing better?

Adherence to nebulised therapies in adolescents with cystic fibrosis is best on week- days during school term-time Rosemary Ball, Kevin W. Southern, Pamela.

Anju Anand, Elizabeth Tullis, Anne Stephenson, Preyanka Abhyankar

D. Stevens, P.J. Oades, N. Armstrong, C.A. Williams

Claire J. Tipping, Rebecca L. Scholes, Narelle S. Cox

Cystic fibrosis mortality trend in Italy from 1970 to 2011

Controversies with Kalydeco: Newspaper coverage in Canada and the United States of the cystic fibrosis “wonder drug” Christen Rachul, Maeghan Toews,

Gerd Döring, Patrick Flume, Harry Heijerman, J. Stuart Elborn

The Journal of Cystic Fibrosis: Sunny perspectives

Efficacy of high dose phylloquinone in correcting vitamin K deficiency in cystic fibrosis Donna Drury, Vijay Laxmi Grey, Guylaine Ferland, Caren Gundberg,

International phase III trial of liprotamase efficacy and safety in pancreatic-insufficient cystic fibrosis patients Drucy Borowitz, Christopher Stevens,

Efficacy and safety of Creon�� 24,000 in subjects with exocrine pancreatic insufficiency due to cystic fibrosis Bruce C. Trapnell, Karen Maguiness, Gavin.

A.H. Gifford Journal of Cystic Fibrosis

EUR-1008 pancreatic enzyme replacement is safe and effective in patients with cystic fibrosis and pancreatic insufficiency Jamie L. Wooldridge, James.

M. Wouthuyzen-Bakker, F.A.J.A. Bodewes, H.J. Verkade

Treatment of resistant distal intestinal obstruction syndrome with a modified antegrade continence enema procedure I.J. Clifton, A.M. Morton, N.S. Ambrose,

Demographics of glucose metabolism in cystic fibrosis

Differences in prevalence and treatment of Pseudomonas aeruginosa in cystic fibrosis centres in Denmark, Norway and Sweden Per Kristian Knudsen, Hanne.

Cystic fibrosis related diabetes in an extremely young patient

Inhalation solutions — Which ones may be mixed

Physiologic endpoints for clinical studies for cystic fibrosis

Maximal daily dose of pancreatic enzyme replacement therapy in infants with cystic fibrosis: A reconsideration Drucy Borowitz, Daniel Gelfond, Karen.

Sophia L. Markantonis, Anna Katelari, Eleni Pappa, Stavros Doudounakis

Colon Cancer in Cystic Fibrosis patients: Is this a growing problem?

Preliminary report of the 13C-mixed triglyceride breath test to assess timing of pancreatic enzyme replacement therapy in children with cystic fibrosis

Cystic fibrosis transmembrane conductance regulator gene variants are associated with autoimmune pancreatitis and slow response to steroid treatment

Anastasios Lekkas, Khin M. Gyi, Margaret E. Hodson

Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis Geraint B. Rogers, Lucas R. Hoffman,

Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: Safety and efficacy in an expanded access program in the United.

Gender differences in treatment adherence among youth with cystic fibrosis: Development of a new questionnaire Joän M. Patterson, Melanie Wall, Jerica.

Disease disclosure in individuals with cystic fibrosis: Association with psychosocial and health outcomes Adrienne P. Borschuk, Robin S. Everhart, Michelle.

Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985–2005 F.A. Millar, N.J. Simmonds, M.E. Hodson Journal.

Kristoffer S. Berlin, Daniel A. Sass, W. Hobart Davies, Matthew D

Successful treatment of cepacia syndrome with a combination of intravenous cyclosporin, antibiotics and oral corticosteroids Francis J. Gilchrist, A.

V. Thompson, N. Mayer-Hamblett, M. Kloster, D. Bilton, P.A. Flume

Comparing age of cystic fibrosis diagnosis and treatment initiation after newborn screening with two common strategies Don B. Sanders, Huichuan J. Lai,

J.E. Spahr, R.B. Love, M. Francois, K. Radford, K.C. Meyer

Voriconazole therapy in children with cystic fibrosis

V. Terlizzi, A. Tosco, R. Tomaiuolo, A. Sepe, N. Amato, A. Casale, C

Randomized trial of efficacy and safety of dornase alfa delivered by eRapid nebulizer in cystic fibrosis patients Gregory S. Sawicki, Will Chou, Karina.

D.F. Waterhouse, A.M. McLaughlin, C.G. Gallagher

‘Peeling paint’ dermatitis as a presenting sign of cystic fibrosis

Lutz Goldbeck, Sven Zerrer, Tim G. Schmitz Journal of Cystic Fibrosis

Khin M. Gyi, Margaret E. Hodson, Magdi Y. Yacoub

David Adeboyeku, Sandra Scott, Margaret E. Hodson

Elisabeth P. Dellon, Margaret W. Leigh, James R. Yankaskas, Terry L

Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience C.R.

Presentation transcript:

Efficacy and safety of PANCREAZE® for treatment of exocrine pancreatic insufficiency due to cystic fibrosis Bruce C. Trapnell, Steven D. Strausbaugh, Marlyn S. Woo, Shin-Yir Tong, Steven A. Silber, Andrew E. Mulberg, Gerhard Leitz Journal of Cystic Fibrosis Volume 10, Issue 5, Pages 350-356 (September 2011) DOI: 10.1016/j.jcf.2011.04.005 Copyright © 2011 Terms and Conditions

Fig. 1 Disposition of the study participants. PERT, pancreatic enzyme replacement therapy; CFA, coefficient of fat absorption. Journal of Cystic Fibrosis 2011 10, 350-356DOI: (10.1016/j.jcf.2011.04.005) Copyright © 2011 Terms and Conditions

Fig. 2 Individual participant data for (A) change in coefficient of fat absorption (CFA) and (B) change in coefficient of nitrogen absorption (CNA) between the open-label phase and double-blind phase for placebo (n=20) or PANCREAZE® (n=20). Journal of Cystic Fibrosis 2011 10, 350-356DOI: (10.1016/j.jcf.2011.04.005) Copyright © 2011 Terms and Conditions